{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,13]],"date-time":"2026-10-13T19:36:48Z","timestamp":1791920208847,"version":"4.3.4"},"reference-count":62,"publisher":"Elsevier BV","issue":"3","license":[{"start":{"date-parts":[[2025,6,1]],"date-time":"2025-06-01T00:00:00Z","timestamp":1748736000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,6,1]],"date-time":"2025-06-01T00:00:00Z","timestamp":1748736000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,3,25]],"date-time":"2025-03-25T00:00:00Z","timestamp":1742860800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/100019779","name":"Qatar National Library","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100019779","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.fr","clinicalkey.jp","clinicalkey.es","clinicalkey.com.au","clinicalkey.com","primary-care-diabetes.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Primary Care Diabetes"],"published-print":{"date-parts":[[2025,6]]},"DOI":"10.1016\/j.pcd.2025.03.008","type":"journal-article","created":{"date-parts":[[2025,4,11]],"date-time":"2025-04-11T19:21:25Z","timestamp":1744399285000},"page":"229-237","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":34,"title":["The promise of tirzepatide: A narrative review of metabolic benefits"],"prefix":"10.1016","volume":"19","author":[{"given":"Sara","family":"Sokary","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1499-5646","authenticated-orcid":false,"given":"Hiba","family":"Bawadi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.pcd.2025.03.008_bib1","unstructured":"World Health Organization, W. Obesity and overweight - Fact Sheet. 2021 [cited February 18,2024; Available from: \u3008https:\/\/www.who.int\/news-room\/fact-sheets\/detail\/obesity-and-overweight\u3009."},{"issue":"10027","key":"10.1016\/j.pcd.2025.03.008_bib2","doi-asserted-by":"crossref","first-page":"1513","DOI":"10.1016\/S0140-6736(16)00618-8","article-title":"Worldwide trends in diabetes since 1980: a pooled analysis of 751 population-based studies with 4\u00b74 million participants","volume":"387","author":"Zhou","year":"2016","journal-title":"Lancet"},{"key":"10.1016\/j.pcd.2025.03.008_bib3","unstructured":"World Health Organization, W. Diatebes - Fact Sheet. 2023 [cited February 18,2024; Available from: \u3008https:\/\/www.who.int\/news-room\/fact-sheets\/detail\/diabetes\u3009."},{"issue":"1","key":"10.1016\/j.pcd.2025.03.008_bib4","doi-asserted-by":"crossref","first-page":"88","DOI":"10.1186\/1471-2458-9-88","article-title":"The incidence of co-morbidities related to obesity and overweight: a systematic review and meta-analysis","volume":"9","author":"Guh","year":"2009","journal-title":"BMC Public Health"},{"issue":"1","key":"10.1016\/j.pcd.2025.03.008_bib5","doi-asserted-by":"crossref","first-page":"20","DOI":"10.1159\/000519444","article-title":"Prevalence of overweight and obesity in type 2 diabetic patients visiting PHC in the Dubai Health Authority","volume":"28","author":"Bawady","year":"2021","journal-title":"Dubai Diabetes Endocrinol. J."},{"issue":"1","key":"10.1016\/j.pcd.2025.03.008_bib6","first-page":"81","article-title":"Obesity & diabetes: an experience at a public sector tertiary care hospital","volume":"30","author":"Ali","year":"2014","journal-title":"Pak. J. Med Sci."},{"issue":"12","key":"10.1016\/j.pcd.2025.03.008_bib7","doi-asserted-by":"crossref","first-page":"2211","DOI":"10.2337\/dc19-0532","article-title":"Racial\/Ethnic disparities in the prevalence of diabetes and prediabetes by BMI: Patient Outcomes Research To Advance Learning (PORTAL) multisite cohort of adults in the U.S","volume":"42","author":"Zhu","year":"2019","journal-title":"Diabetes Care"},{"key":"10.1016\/j.pcd.2025.03.008_bib8","doi-asserted-by":"crossref","DOI":"10.1016\/j.clinthera.2023.12.014","article-title":"Use of dulaglutide, semaglutide, and tirzepatide in diabetes and weight management","author":"Powell","year":"2024","journal-title":"Clin. Ther."},{"issue":"3","key":"10.1016\/j.pcd.2025.03.008_bib9","doi-asserted-by":"crossref","DOI":"10.1111\/obr.13543","article-title":"Comparative effectiveness of glucagon-like peptide-1 receptor agonists for the management of obesity in adults without diabetes: a network meta-analysis of randomized clinical trials","volume":"24","author":"Alkhezi","year":"2023","journal-title":"Obes. Rev."},{"key":"10.1016\/j.pcd.2025.03.008_bib10","unstructured":"Agency, E.M. Mounjaro (tirzepatide) How is Mounjaro used? How does Mounjaro work? 2023 14\/09\/2024]; Available from: \u3008https:\/\/www.ema.europa.eu\/en\/documents\/overview\/mounjaro-epar-medicine-overview_en.pdf\u3009."},{"issue":"2","key":"10.1016\/j.pcd.2025.03.008_bib11","doi-asserted-by":"crossref","first-page":"106","DOI":"10.7570\/jomes23032","article-title":"Approved anti-obesity medications in 2022 KSSO guidelines and the promise of phase 3 clinical trials: anti-obesity drugs in the sky and on the horizon","volume":"32","author":"Jeon","year":"2023","journal-title":"J. Obes. Metab. Syndr."},{"key":"10.1016\/j.pcd.2025.03.008_bib12","unstructured":"Administration, F.A.D. Highlights of Prescribing Information. 2022 14\/09\/2024]; Available from: \u3008https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2022\/215866s000lbl.pdf\u3009."},{"issue":"1-2","key":"10.1016\/j.pcd.2025.03.008_bib13","doi-asserted-by":"crossref","first-page":"8","DOI":"10.1111\/j.2040-1124.2010.00022.x","article-title":"GIP and GLP-1, the two incretin hormones: Similarities and differences","volume":"1","author":"Seino","year":"2010","journal-title":"J. Diabetes Invest."},{"issue":"6","key":"10.1016\/j.pcd.2025.03.008_bib14","doi-asserted-by":"crossref","first-page":"2131","DOI":"10.1053\/j.gastro.2007.03.054","article-title":"Biology of incretins: GLP-1 and GIP","volume":"132","author":"Baggio","year":"2007","journal-title":"Gastroenterology"},{"issue":"6","key":"10.1016\/j.pcd.2025.03.008_bib15","doi-asserted-by":"crossref","first-page":"525","DOI":"10.1016\/S2213-8587(15)00482-9","article-title":"The incretin effect in healthy individuals and those with type 2 diabetes: physiology, pathophysiology, and response to therapeutic interventions","volume":"4","author":"Nauck","year":"2016","journal-title":"Lancet Diabetes Endocrinol."},{"key":"10.1016\/j.pcd.2025.03.008_bib16","doi-asserted-by":"crossref","first-page":"72","DOI":"10.1016\/j.molmet.2019.09.010","article-title":"Glucagon-like peptide 1 (GLP-1)","volume":"30","author":"M\u00fcller","year":"2019","journal-title":"Mol. Metab."},{"key":"10.1016\/j.pcd.2025.03.008_bib17","doi-asserted-by":"crossref","DOI":"10.1016\/j.phrs.2019.104391","article-title":"More than just an enzyme: dipeptidyl peptidase-4 (DPP-4) and its association with diabetic kidney remodelling","volume":"147","author":"Gupta","year":"2019","journal-title":"Pharmacol. Res."},{"issue":"1","key":"10.1016\/j.pcd.2025.03.008_bib18","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1530\/JOE-15-0247","article-title":"GLP1- and GIP-producing cells rarely overlap and differ by bombesin receptor-2 expression and responsiveness","volume":"228","author":"Svendsen","year":"2016","journal-title":"J. Endocrinol."},{"issue":"4","key":"10.1016\/j.pcd.2025.03.008_bib19","doi-asserted-by":"crossref","DOI":"10.3390\/nu13041158","article-title":"Gastric sensory and motor functions and energy intake in health and obesity-therapeutic implications","volume":"13","author":"Cifuentes","year":"2021","journal-title":"Nutrients"},{"issue":"8","key":"10.1016\/j.pcd.2025.03.008_bib20","doi-asserted-by":"crossref","first-page":"673","DOI":"10.1111\/dom.12251","article-title":"The extra-pancreatic effects of GLP-1 receptor agonists: a focus on the cardiovascular, gastrointestinal and central nervous systems","volume":"16","author":"Seufert","year":"2014","journal-title":"Diabetes Obes. Metab."},{"issue":"3","key":"10.1016\/j.pcd.2025.03.008_bib21","doi-asserted-by":"crossref","first-page":"205","DOI":"10.1056\/NEJMoa2206038","article-title":"Tirzepatide once weekly for the treatment of obesity","volume":"387","author":"Jastreboff","year":"2022","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.pcd.2025.03.008_bib22","unstructured":"Khashayar, F. and P. Preeti, Tirzepatide - StatPearls - NCBI Bookshelf. 2024."},{"key":"10.1016\/j.pcd.2025.03.008_bib23","doi-asserted-by":"crossref","first-page":"1547","DOI":"10.2147\/DDDT.S358989","article-title":"Designing a dual GLP-1R\/GIPR agonist from tirzepatide: comparing residues between tirzepatide, GLP-1, and GIP","volume":"16","author":"Wang","year":"2022","journal-title":"Drug Des. Dev. Ther."},{"issue":"8","key":"10.1016\/j.pcd.2025.03.008_bib24","doi-asserted-by":"crossref","first-page":"1049","DOI":"10.1007\/s40262-021-01012-2","article-title":"Effects of renal impairment on the pharmacokinetics of the dual GIP and GLP-1 receptor agonist tirzepatide","volume":"60","author":"Urva","year":"2021","journal-title":"Clin. Pharmacokinet."},{"key":"10.1016\/j.pcd.2025.03.008_bib25","unstructured":"FDA Clinical Pharmacology Review(s). Center for Drug Evaluation and Research. Application Number: 215866Orig1S000. Tirzepatide."},{"key":"10.1016\/j.pcd.2025.03.008_bib26","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1016\/j.molmet.2018.09.009","article-title":"LY3298176, a novel dual GIP and GLP-1 receptor agonist for the treatment of type 2 diabetes mellitus: from discovery to clinical proof of concept","volume":"18","author":"Coskun","year":"2018","journal-title":"Mol. Metab."},{"issue":"6","key":"10.1016\/j.pcd.2025.03.008_bib27","doi-asserted-by":"crossref","first-page":"503","DOI":"10.1056\/NEJMoa2107519","article-title":"Tirzepatide versus semaglutide once weekly in patients with type 2 diabetes","volume":"385","author":"Fr\u00edas","year":"2021","journal-title":"N. Engl. J. Med"},{"issue":"6","key":"10.1016\/j.pcd.2025.03.008_bib28","doi-asserted-by":"crossref","first-page":"534","DOI":"10.1001\/jama.2022.0078","article-title":"Effect of SUbcutaneous Tirzepatide Vs Placebo Added to Titrated Insulin Glargine on Glycemic Control in Patients with Type 2 diabetes: the SURPASS-5 randomized clinical trial","volume":"327","author":"Dahl","year":"2022","journal-title":"Jama"},{"issue":"17","key":"10.1016\/j.pcd.2025.03.008_bib29","doi-asserted-by":"crossref","first-page":"1631","DOI":"10.1001\/jama.2023.20294","article-title":"Tirzepatide vs insulin lispro added to basal insulin in type 2 diabetes: the SURPASS-6 randomized clinical trial","volume":"330","author":"Rosenstock","year":"2023","journal-title":"JAMA"},{"issue":"10402","key":"10.1016\/j.pcd.2025.03.008_bib30","doi-asserted-by":"crossref","first-page":"613","DOI":"10.1016\/S0140-6736(23)01200-X","article-title":"Tirzepatide once weekly for the treatment of obesity in people with type 2 diabetes (SURMOUNT-2): a double-blind, randomised, multicentre, placebo-controlled, phase 3 trial","volume":"402","author":"Garvey","year":"2023","journal-title":"Lancet"},{"issue":"11","key":"10.1016\/j.pcd.2025.03.008_bib31","doi-asserted-by":"crossref","first-page":"2909","DOI":"10.1038\/s41591-023-02597-w","article-title":"Tirzepatide after intensive lifestyle intervention in adults with overweight or obesity: the SURMOUNT-3 phase 3 trial","volume":"29","author":"Wadden","year":"2023","journal-title":"Nat. Med."},{"issue":"10300","key":"10.1016\/j.pcd.2025.03.008_bib32","doi-asserted-by":"crossref","first-page":"583","DOI":"10.1016\/S0140-6736(21)01443-4","article-title":"Once-weekly tirzepatide versus once-daily insulin degludec as add-on to metformin with or without SGLT2 inhibitors in patients with type 2 diabetes (SURPASS-3): a randomised, open-label, parallel-group, phase 3 trial","volume":"398","author":"Ludvik","year":"2021","journal-title":"Lancet"},{"key":"10.1016\/j.pcd.2025.03.008_bib33","article-title":"Comparative effectiveness of GLP-1 receptor agonists on glycaemic control, body weight, and lipid profile for type 2 diabetes: systematic review and network meta-analysis","volume":"384","author":"Yao","year":"2024","journal-title":"Bmj"},{"issue":"4","key":"10.1016\/j.pcd.2025.03.008_bib34","doi-asserted-by":"crossref","first-page":"1454","DOI":"10.1111\/dom.15446","article-title":"Efficacy and safety of tirzepatide in people with type 2 diabetes by baseline body mass index: an exploratory subgroup analysis of SURPASS-AP-Combo","volume":"26","author":"Ma","year":"2024","journal-title":"Diabetes, Obes. Metab."},{"issue":"3","key":"10.1016\/j.pcd.2025.03.008_bib35","doi-asserted-by":"crossref","DOI":"10.15562\/bmj.v7i3.806","article-title":"Mean Platelet Volume (MPV) as an inflammatory marker in type 2 diabetes mellitus and obesity","volume":"7","author":"Aktas","year":"2018","journal-title":"Bali Med. J."},{"issue":"18","key":"10.1016\/j.pcd.2025.03.008_bib36","doi-asserted-by":"crossref","first-page":"5952","DOI":"10.3390\/jcm12185952","article-title":"Association between the prognostic nutritional index and chronic microvascular complications in patients with type 2 diabetes mellitus","volume":"12","author":"Aktas","year":"2023","journal-title":"J. Clin. Med."},{"issue":"1","key":"10.1016\/j.pcd.2025.03.008_bib37","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1590\/1806-9282.65.1.9","article-title":"Serum uric acid to HDL-cholesterol ratio is a strong predictor of metabolic syndrome in type 2 diabetes mellitus","volume":"65","author":"Kocak","year":"2019","journal-title":"Rev. Assoc. Med Bras."},{"issue":"3","key":"10.1016\/j.pcd.2025.03.008_bib38","first-page":"145","article-title":"A novel marker for prediabetic conditions: uric acid-to-HDL cholesterol ratio","volume":"125","author":"Balci","year":"2024","journal-title":"Bratisl. Lek. Listy"},{"issue":"4","key":"10.1016\/j.pcd.2025.03.008_bib39","doi-asserted-by":"crossref","first-page":"549","DOI":"10.1590\/1806-9282.20201005","article-title":"The association between serum uric acid to high density lipoprotein-cholesterol ratio and non-alcoholic fatty liver disease: the abund study","volume":"67","author":"Kosekli","year":"2021","journal-title":"Rev. Assoc. Med Bras."},{"issue":"5","key":"10.1016\/j.pcd.2025.03.008_bib40","doi-asserted-by":"crossref","first-page":"519","DOI":"10.1080\/00325481.2023.2214058","article-title":"Is serum uric acid-to-HDL cholesterol ratio elevation associated with diabetic kidney injury?","volume":"135","author":"Aktas","year":"2023","journal-title":"Post. Med"},{"issue":"1","key":"10.1016\/j.pcd.2025.03.008_bib41","doi-asserted-by":"crossref","first-page":"242","DOI":"10.1186\/s12933-024-02319-7","article-title":"Bridging the gap between GLP1-receptor agonists and cardiovascular outcomes: evidence for the role of tirzepatide","volume":"23","author":"Taktaz","year":"2024","journal-title":"Cardiovasc. Diabetol."},{"key":"10.1016\/j.pcd.2025.03.008_bib42","article-title":"Evidence that tirzepatide protects against diabetes-related cardiac damages","author":"Taktaz","year":"2024","journal-title":"Meta-Analysis"},{"issue":"1","key":"10.1016\/j.pcd.2025.03.008_bib43","doi-asserted-by":"crossref","first-page":"8","DOI":"10.1186\/s12944-024-02416-2","article-title":"Exploring the molecular mechanisms of tirzepatide in alleviating metabolic dysfunction-associated fatty liver in mice through integration of metabolomics, lipidomics, and proteomics","volume":"24","author":"Liang","year":"2025","journal-title":"Lipids Health Dis."},{"issue":"1","key":"10.1016\/j.pcd.2025.03.008_bib44","doi-asserted-by":"crossref","first-page":"148","DOI":"10.1111\/dom.14553","article-title":"The dual glucose-dependent insulinotropic polypeptide and glucagon-like peptide-1 receptor agonist tirzepatide improves cardiovascular risk biomarkers in patients with type 2 diabetes: a post hoc analysis","volume":"24","author":"Wilson","year":"2022","journal-title":"Diabetes Obes. Metab."},{"issue":"10295","key":"10.1016\/j.pcd.2025.03.008_bib45","doi-asserted-by":"crossref","first-page":"143","DOI":"10.1016\/S0140-6736(21)01324-6","article-title":"Efficacy and safety of a novel dual GIP and GLP-1 receptor agonist tirzepatide in patients with type 2 diabetes (SURPASS-1): a double-blind, randomised, phase 3 trial","volume":"398","author":"Rosenstock","year":"2021","journal-title":"Lancet"},{"issue":"6","key":"10.1016\/j.pcd.2025.03.008_bib46","doi-asserted-by":"crossref","first-page":"393","DOI":"10.1016\/S2213-8587(22)00070-5","article-title":"Effect of tirzepatide versus insulin degludec on liver fat content and abdominal adipose tissue in people with type 2 diabetes (SURPASS-3 MRI): a substudy of the randomised, open-label, parallel-group, phase 3 SURPASS-3 trial","volume":"10","author":"Gastaldelli","year":"2022","journal-title":"Lancet Diabetes Endocrinol."},{"issue":"5","key":"10.1016\/j.pcd.2025.03.008_bib47","doi-asserted-by":"crossref","first-page":"998","DOI":"10.2337\/dc22-1710","article-title":"Tirzepatide reduces appetite, energy intake, and fat mass in people with type 2 diabetes","volume":"46","author":"Heise","year":"2023","journal-title":"Diabetes Care"},{"issue":"1","key":"10.1016\/j.pcd.2025.03.008_bib48","doi-asserted-by":"crossref","first-page":"38","DOI":"10.1001\/jama.2023.24945","article-title":"Continued treatment with tirzepatide for maintenance of weight reduction in adults with obesity: the SURMOUNT-4 randomized clinical trial","volume":"331","author":"Aronne","year":"2024","journal-title":"Jama"},{"issue":"4","key":"10.1016\/j.pcd.2025.03.008_bib49","doi-asserted-by":"crossref","first-page":"841","DOI":"10.1002\/oby.23374","article-title":"Beyond appetite regulation: targeting energy expenditure, fat oxidation, and lean mass preservation for sustainable weight loss","volume":"30","author":"Christoffersen","year":"2022","journal-title":"Obes. (Silver Spring)"},{"key":"10.1016\/j.pcd.2025.03.008_bib50","doi-asserted-by":"crossref","DOI":"10.1038\/oby.2004.282","article-title":"Efficacy of lifestyle modification for long-term weight control","volume":"12","author":"Wadden","year":"2004","journal-title":"Obes. Res"},{"issue":"1(1","key":"10.1016\/j.pcd.2025.03.008_bib51","article-title":"Describing the weight-reduced state: physiology, behavior, and interventions","volume":"29","author":"Aronne","year":"2021","journal-title":"Obes. (Silver Spring)"},{"issue":"1","key":"10.1016\/j.pcd.2025.03.008_bib52","article-title":"Appetite regulation and physical activity \u2013 an energy balance perspective","volume":"8","author":"Gibbons","year":"2015","journal-title":"Hamdan Med. J."},{"issue":"10313","key":"10.1016\/j.pcd.2025.03.008_bib53","doi-asserted-by":"crossref","first-page":"1811","DOI":"10.1016\/S0140-6736(21)02188-7","article-title":"Tirzepatide versus insulin glargine in type 2 diabetes and increased cardiovascular risk (SURPASS-4): a randomised, open-label, parallel-group, multicentre, phase 3 trial","volume":"398","author":"Del Prato","year":"2021","journal-title":"Lancet"},{"issue":"9","key":"10.1016\/j.pcd.2025.03.008_bib54","doi-asserted-by":"crossref","first-page":"623","DOI":"10.1016\/S2213-8587(22)00188-7","article-title":"Efficacy and safety of tirzepatide monotherapy compared with dulaglutide in Japanese patients with type 2 diabetes (SURPASS J-mono): a double-blind, multicentre, randomised, phase 3 trial","volume":"10","author":"Inagaki","year":"2022","journal-title":"Lancet Diabetes Endocrinol."},{"issue":"9","key":"10.1016\/j.pcd.2025.03.008_bib55","doi-asserted-by":"crossref","first-page":"634","DOI":"10.1016\/S2213-8587(22)00187-5","article-title":"Safety and efficacy of tirzepatide as an add-on to single oral antihyperglycaemic medication in patients with type 2 diabetes in Japan (SURPASS J-combo): a multicentre, randomised, open-label, parallel-group, phase 3 trial","volume":"10","author":"Kadowaki","year":"2022","journal-title":"Lancet Diabetes Endocrinol."},{"issue":"6","key":"10.1016\/j.pcd.2025.03.008_bib56","doi-asserted-by":"crossref","first-page":"418","DOI":"10.1016\/S2213-8587(22)00085-7","article-title":"Effects of subcutaneous tirzepatide versus placebo or semaglutide on pancreatic islet function and insulin sensitivity in adults with type 2 diabetes: a multicentre, randomised, double-blind, parallel-arm, phase 1 clinical trial","volume":"10","author":"Heise","year":"2022","journal-title":"Lancet Diabetes Endocrinol."},{"issue":"2","key":"10.1016\/j.pcd.2025.03.008_bib57","doi-asserted-by":"crossref","first-page":"239","DOI":"10.1111\/dom.14572","article-title":"A phase 1 multiple-ascending dose study of tirzepatide in Japanese participants with type 2 diabetes","volume":"24","author":"Furihata","year":"2022","journal-title":"Diabetes Obes. Metab."},{"issue":"6","key":"10.1016\/j.pcd.2025.03.008_bib58","doi-asserted-by":"crossref","first-page":"938","DOI":"10.1111\/dom.13979","volume":"22","author":"Frias","year":"2020","journal-title":"Diabetes Obes. Metab."},{"key":"10.1016\/j.pcd.2025.03.008_bib59","unstructured":"Eli Lilly and Company. Highlights of prescribing information. 2023 April, 2024 Fibruary 24, 2024]; Available from: \u3008https:\/\/uspl.lilly.com\/mounjaro\/mounjaro.html#s15\u3009."},{"issue":"1","key":"10.1016\/j.pcd.2025.03.008_bib60","article-title":"A case report of systemic allergic reaction to the dual glucose-dependent insulinotropic polypeptide\/glucagon-like peptide-1 receptor agonist tirzepatide","volume":"16","author":"Le","year":"2024","journal-title":"Cureus"},{"issue":"13","key":"10.1016\/j.pcd.2025.03.008_bib61","doi-asserted-by":"crossref","DOI":"10.3390\/molecules27134315","article-title":"Tirzepatide, a new era of dual-targeted treatment for diabetes and obesity: a mini-review","volume":"27","author":"Chavda","year":"2022","journal-title":"Molecules"},{"key":"10.1016\/j.pcd.2025.03.008_bib62","unstructured":"Tirzepatide, in LiverTox: Clinical and Research Information on Drug-Induced Liver Injury. 2012, National Institute of Diabetes and Digestive and Kidney Diseases: Bethesda (MD)."}],"container-title":["Primary Care Diabetes"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1751991825000816?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1751991825000816?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,5,10]],"date-time":"2025-05-10T01:49:08Z","timestamp":1746841748000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1751991825000816"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,6]]},"references-count":62,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2025,6]]}},"alternative-id":["S1751991825000816"],"URL":"https:\/\/doi.org\/10.1016\/j.pcd.2025.03.008","relation":{},"ISSN":["1751-9918"],"issn-type":[{"value":"1751-9918","type":"print"}],"subject":[],"published":{"date-parts":[[2025,6]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"The promise of tirzepatide: A narrative review of metabolic benefits","name":"articletitle","label":"Article Title"},{"value":"Primary Care Diabetes","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.pcd.2025.03.008","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 The Author(s). Published by Elsevier Ltd on behalf of Primary Care Diabetes Europe.","name":"copyright","label":"Copyright"}]}}